Use of convalescent plasma in COVID-19 patients with immunosuppression

Jonathon W. Senefeld; Stephen A. Klassen; Shane K. Ford; Katherine A. Senese; Chad C. Wiggins; Bruce C. Bostrom; Michael A. Thompson; Sarah E. Baker; Wayne T. Nicholson; Patrick W. Johnson; Rickey E. Carter; Jeffrey P. Henderson; William R. Hartman; Liise anne Pirofski; R. Scott Wright; De Lisa Fairweather; Katelyn A. Bruno; Nigel S. Paneth; Arturo Casadevall; Michael J. Joyner

doi:10.1111/trf.16525

Use of convalescent plasma in COVID-19 patients with immunosuppression

Jonathon W. Senefeld, Stephen A. Klassen, Shane K. Ford, Katherine A. Senese, Chad C. Wiggins, Bruce C. Bostrom, Michael A. Thompson, Sarah E. Baker, Wayne T. Nicholson, Patrick W. Johnson, Rickey E. Carter, Jeffrey P. Henderson, William R. Hartman, Liise anne Pirofski, R. Scott Wright, De Lisa Fairweather, Katelyn A. Bruno, Nigel S. Paneth, Arturo Casadevall, Michael J. Joyner

Bloomberg School of Public Health

Research output: Contribution to journal › Review article › peer-review

Abstract

In the absence of effective countermeasures, human convalescent plasma has been widely used to treat severe acute respiratory syndrome coronavirus 2, the causative agent of novel coronavirus disease 19 (COVID-19), including among patients with innate or acquired immunosuppression. However, the association between COVID-19-associated mortality in patients with immunosuppression and therapeutic use of convalescent plasma is unknown. We review 75 reports, including one large matched-control registry study of 143 COVID-19 patients with hematological malignancies, and 51 case reports and 23 case series representing 238 COVID-19 patients with immunosuppression. We review clinical features and treatment protocols of COVID-19 patients with immunosuppression after treatment with human convalescent plasma. We also discuss the time course and clinical features of recovery. The available data from case reports and case series provide evidence suggesting a mortality benefit and rapid clinical improvement in patients with several forms of immunosuppression following COVID-19 convalescent plasma transfusion. The utility of convalescent plasma or other forms of antibody therapy in immune-deficient and immune-suppressed patients with COVID-19 warrants further investigation.

Original language	English (US)
Pages (from-to)	2503-2511
Number of pages	9
Journal	Transfusion
Volume	61
Issue number	8
DOIs	https://doi.org/10.1111/trf.16525
State	Published - Aug 2021

Keywords

FFP transfusion
transfusion practices (oncology–hematology)
transplantation—solid organ

ASJC Scopus subject areas

Immunology and Allergy
Immunology
Hematology

Access to Document

10.1111/trf.16525

Cite this

Senefeld, J. W., Klassen, S. A., Ford, S. K., Senese, K. A., Wiggins, C. C., Bostrom, B. C., Thompson, M. A., Baker, S. E., Nicholson, W. T., Johnson, P. W., Carter, R. E., Henderson, J. P., Hartman, W. R., Pirofski, L. A., Wright, R. S., Fairweather, D. L., Bruno, K. A., Paneth, N. S., Casadevall, A., & Joyner, M. J. (2021). Use of convalescent plasma in COVID-19 patients with immunosuppression. Transfusion, 61(8), 2503-2511. https://doi.org/10.1111/trf.16525

Senefeld, JW, Klassen, SA, Ford, SK, Senese, KA, Wiggins, CC, Bostrom, BC, Thompson, MA, Baker, SE, Nicholson, WT, Johnson, PW, Carter, RE, Henderson, JP, Hartman, WR, Pirofski, LA, Wright, RS, Fairweather, DL, Bruno, KA, Paneth, NS, Casadevall, A & Joyner, MJ 2021, 'Use of convalescent plasma in COVID-19 patients with immunosuppression', Transfusion, vol. 61, no. 8, pp. 2503-2511. https://doi.org/10.1111/trf.16525

@article{8eac1b4958b3429bbdd92d114bc1c906,

title = "Use of convalescent plasma in COVID-19 patients with immunosuppression",

abstract = "In the absence of effective countermeasures, human convalescent plasma has been widely used to treat severe acute respiratory syndrome coronavirus 2, the causative agent of novel coronavirus disease 19 (COVID-19), including among patients with innate or acquired immunosuppression. However, the association between COVID-19-associated mortality in patients with immunosuppression and therapeutic use of convalescent plasma is unknown. We review 75 reports, including one large matched-control registry study of 143 COVID-19 patients with hematological malignancies, and 51 case reports and 23 case series representing 238 COVID-19 patients with immunosuppression. We review clinical features and treatment protocols of COVID-19 patients with immunosuppression after treatment with human convalescent plasma. We also discuss the time course and clinical features of recovery. The available data from case reports and case series provide evidence suggesting a mortality benefit and rapid clinical improvement in patients with several forms of immunosuppression following COVID-19 convalescent plasma transfusion. The utility of convalescent plasma or other forms of antibody therapy in immune-deficient and immune-suppressed patients with COVID-19 warrants further investigation.",

keywords = "FFP transfusion, transfusion practices (oncology–hematology), transplantation—solid organ",

author = "Senefeld, {Jonathon W.} and Klassen, {Stephen A.} and Ford, {Shane K.} and Senese, {Katherine A.} and Wiggins, {Chad C.} and Bostrom, {Bruce C.} and Thompson, {Michael A.} and Baker, {Sarah E.} and Nicholson, {Wayne T.} and Johnson, {Patrick W.} and Carter, {Rickey E.} and Henderson, {Jeffrey P.} and Hartman, {William R.} and Pirofski, {Liise anne} and Wright, {R. Scott} and Fairweather, {De Lisa} and Bruno, {Katelyn A.} and Paneth, {Nigel S.} and Arturo Casadevall and Joyner, {Michael J.}",

note = "Publisher Copyright: {\textcopyright} 2021 The Authors. Transfusion published by Wiley Periodicals LLC. on behalf of AABB.",

year = "2021",

month = aug,

doi = "10.1111/trf.16525",

language = "English (US)",

volume = "61",

pages = "2503--2511",

journal = "Transfusion",

issn = "0041-1132",

publisher = "Wiley-Blackwell",

number = "8",

}

TY - JOUR

T1 - Use of convalescent plasma in COVID-19 patients with immunosuppression

AU - Senefeld, Jonathon W.

AU - Klassen, Stephen A.

AU - Ford, Shane K.

AU - Senese, Katherine A.

AU - Wiggins, Chad C.

AU - Bostrom, Bruce C.

AU - Thompson, Michael A.

AU - Baker, Sarah E.

AU - Nicholson, Wayne T.

AU - Johnson, Patrick W.

AU - Carter, Rickey E.

AU - Henderson, Jeffrey P.

AU - Hartman, William R.

AU - Pirofski, Liise anne

AU - Wright, R. Scott

AU - Fairweather, De Lisa

AU - Bruno, Katelyn A.

AU - Paneth, Nigel S.

AU - Casadevall, Arturo

AU - Joyner, Michael J.

PY - 2021/8

Y1 - 2021/8

N2 - In the absence of effective countermeasures, human convalescent plasma has been widely used to treat severe acute respiratory syndrome coronavirus 2, the causative agent of novel coronavirus disease 19 (COVID-19), including among patients with innate or acquired immunosuppression. However, the association between COVID-19-associated mortality in patients with immunosuppression and therapeutic use of convalescent plasma is unknown. We review 75 reports, including one large matched-control registry study of 143 COVID-19 patients with hematological malignancies, and 51 case reports and 23 case series representing 238 COVID-19 patients with immunosuppression. We review clinical features and treatment protocols of COVID-19 patients with immunosuppression after treatment with human convalescent plasma. We also discuss the time course and clinical features of recovery. The available data from case reports and case series provide evidence suggesting a mortality benefit and rapid clinical improvement in patients with several forms of immunosuppression following COVID-19 convalescent plasma transfusion. The utility of convalescent plasma or other forms of antibody therapy in immune-deficient and immune-suppressed patients with COVID-19 warrants further investigation.

AB - In the absence of effective countermeasures, human convalescent plasma has been widely used to treat severe acute respiratory syndrome coronavirus 2, the causative agent of novel coronavirus disease 19 (COVID-19), including among patients with innate or acquired immunosuppression. However, the association between COVID-19-associated mortality in patients with immunosuppression and therapeutic use of convalescent plasma is unknown. We review 75 reports, including one large matched-control registry study of 143 COVID-19 patients with hematological malignancies, and 51 case reports and 23 case series representing 238 COVID-19 patients with immunosuppression. We review clinical features and treatment protocols of COVID-19 patients with immunosuppression after treatment with human convalescent plasma. We also discuss the time course and clinical features of recovery. The available data from case reports and case series provide evidence suggesting a mortality benefit and rapid clinical improvement in patients with several forms of immunosuppression following COVID-19 convalescent plasma transfusion. The utility of convalescent plasma or other forms of antibody therapy in immune-deficient and immune-suppressed patients with COVID-19 warrants further investigation.

KW - FFP transfusion

KW - transfusion practices (oncology–hematology)

KW - transplantation—solid organ

UR - http://www.scopus.com/inward/record.url?scp=85107317534&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85107317534&partnerID=8YFLogxK

U2 - 10.1111/trf.16525

DO - 10.1111/trf.16525

M3 - Review article

C2 - 34036587

AN - SCOPUS:85107317534

SN - 0041-1132

VL - 61

SP - 2503

EP - 2511

JO - Transfusion

JF - Transfusion

IS - 8

ER -

Use of convalescent plasma in COVID-19 patients with immunosuppression

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this